AbbVie Inc.报告收入丰厚,股息增加,但一个主要投资者的股权略有下降。 AbbVie Inc. reported strong earnings, raised its dividend, yet saw a slight drop in one major investor's stake.

Canandaigua国家银行和信托公司将其在AbbVie公司的股份减少了1.5%,而Oliver Luxxe资产有限公司等其他投资者则增加了其股份。 Canandaigua National Bank & Trust Co. reduced its stake in AbbVie Inc. by 1.5%, while other investors like Oliver Luxxe Assets LLC increased their holdings. AbbVie报告一个强劲的季度,将EPS的估计数打了0.8美元,并将季度红利提高到1.64美元,即3.65%的收益率。 AbbVie reported a strong quarter, beating EPS estimates by $0.08, and raised its quarterly dividend to $1.64, a 3.65% yield. 该制药公司以其药品Humira闻名,其市场上限为3 177.8亿美元,价格与收入之比为62 44。 The pharmaceutical company, known for its drug Humira, has a market cap of $317.78 billion and a price-to-earnings ratio of 62.44. 分析师给予AbbVie“机动购买”评级,平均价格目标是205.70美元。 Analysts have given AbbVie a "Moderate Buy" rating with an average price target of $205.70.